Alnylam CEO John Maraganore – An Interview With “The Pink Sheet” DAILY (Part 1 of 2)

The RNAi-pioneering biotech is sitting in a different position than it was a year ago, about to take its lead candidate into pivotal studies and with a new partnership with Arrowhead and $87 million in proceeds from one of the largest follow-on public offerings in recent memory by a biotech firm.